PHA121-C001 enrolled healthy volunteers, who received single doses up to 22 mg given as an oral solution.
Pharmacokinetic cohorts had six participants per dose, and the food effect was assessed in one cohort of six participants at 22 mg. The higher AUCinf after a high-calorie, high-fat breakfast was reported as “mainly caused by one outlier”, and the AUC increase is reported as 49% and as 42% in different documents.
The pharmacodynamic evidence comes from a bradykinin challenge in 16 healthy volunteers receiving 12 or 22 mg, a surrogate used for icatibant dose selection, and the results were compared with published icatibant results.
Safety was followed for 72 hours after a single dose.
The results are reported in two posters described in a company press release and in the company's registration statement.